Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02502786
Recruitment Status : Recruiting
First Posted : July 20, 2015
Last Update Posted : June 4, 2021
Sponsor:
Collaborators:
Children's Hospital Los Angeles
M.D. Anderson Cancer Center
Y-mAbs Therapeutics
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : July 2022